This trial is looking at the use of bamlanivimab or casirivimab + imdevimab for the treatment of mild to moderate coronavirus disease 2019 (COVID19) in adults and pediatric patients.
1 Primary · 0 Secondary · Reporting Duration: six weeks from monoclonal administration
1000 Total Participants · 2 Treatment Groups
Primary Treatment: BAMLANIVIMAB · No Placebo Group · Phase 2
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: